Cristóbal Belda-Iniesta

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 568 citations · Full text

Medicine, Immunology, Pathology +5

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 384 citations · Full text

DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients

Noemí Garcia‐Romero, Josefa Carrión-Navarro, Susana Esteban-Rubio et al. · Oncotarget · 2016 · 266 citations · Full text

Tumor Innervation, Biological Microenvironments, Peripheral Blood +20

Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis

Antonio Isidoro, E. Casado, Andrés Redondo et al. · Carcinogenesis · 2005 · 171 citations · Full text

KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis

Paloma Cejas, Miriam López-Gómez, Cristina Aguayo et al. · PLoS ONE · 2009 · 153 citations · Full text